Skip to main content
. 2020 Nov 11;10:579673. doi: 10.3389/fonc.2020.579673

Figure 2.

Figure 2

Identification of oncogenic potential of MEIS1–FOXO1 fusion gene. (A) Schematic DNA representation of novel MEIS1–FOXO1 rearrangement (red, MEIS1; blue, FOXO1). (B) Fusion protein representation of novel MEIS1–FOXO1 rearrangement (red box, MEIS1 PKNOX N domain; pink box, homeobox KN domain; dark blue box, forkhead domain; light blue box, KIX-binding domain; gray blue box, transactivation domain). (C) MEIS1–FOXO1 potentiated leukemia transformation in Ba/F3 cell model. Effects of MEIS1–FOXO1 fusion genes on Ba/F3 transformation. Following transduction of empty vector, MEIS1–FOXO1, NRASG12D, or combination, Ba/F3 cells were cultured in IL-3 depleted medium with cytokine-independent cell growth as a measure of oncogenic transformation. Number of viable cells was evaluated daily. (D) MEIS1–FOXO1 fusion genes and proliferation of mouse hematopoietic progenitor cell Ba/F3. Ba/F3 cells were lentivirally transduced with empty vector (black), NRASG12D (blue), MEIS1–FOXO1 (green), or combination of NRASG12D and MEIS1–FOXO1 (red) and then cultured in the presence of IL-3 (10 ng/ml). After 48 h, cell cycle distribution was evaluated using standard PI staining protocol. Statistical significance, determined using the two-sided unpaired t-test, is indicated by **P < 0.01.